Abstract 3969
Background
Overall colorectal cancer (CRC) incidence and mortality are declining due to cancer screening in older patients population, however, the incidence of CRC is increasing in younger adults (<50 years) among several countries, mostly in the United States and Europe. This study aimed to evaluateclinicopathological characteristics of adolescent and young adult (AYA) onset sporadic CRC and outcome in Thai patients.
Methods
Medical record of patients who were diagnosed adenocarcinoma of colorectal cancer at Siriraj Hospital between 2007 and 2018 were retrospectively reviewed. The patients were classified into 2 groups: AYA-onset CRC (age 15-39 years) and adult-onset CRC (age >50 years). Associations between sporadic microsatellite stable (MSS) AYA- /adult-onset CRC and clinicaopathological features and outcome were evaluated.
Results
A total 202 patients were diagnosed with AYA-onset CRC with no known history of familial CRC syndromes, 116 had data on mismatch repair status; 94 confirmed MSS CRC. AYA-onset CRC patients were commonly found with left-sided rather than right-sided tumors (77.7% vs 21.8%) and late stage of disease (72.7% in stage III-IV vs 24.7% in stage I-II). Compared with adult-onset CRC (195 patients), AYA-onset MSS CRC had more patients with female gender (p = 0.042), signet ring cell/mucinous histology (P = 0.039), and perineuralinvasion (P = 0.004). On univariate analysis, male gender and mucinous/signet ring cell histology had significantly worse OS (P = 0.003 and P = 0.016, respectively) and remained significant in multivariate analysis. There was no differences in terms of DFS or OS in both age groups.
Conclusions
Sporadic MSS AYA-onset CRC in Thai patients was associated with female gender and aggressive pathological characteristics. However, there was no difference in survival outcome between AYA-onset and adult-onset groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Siriraj Research Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract